16+ hour, 1+ min ago  (225+ words) Cancer Network Background One of the main causes of disease recurrence and mortality in breast cancer treatment is therapeutic resistance, which continues to be a significant challenge A growing body of research suggests that the self-renewal ability and phenotypic flexibility…...

11+ hour, 38+ min ago  (303+ words) Cancer Network Background Primary neuroendocrine carcinoma of the breast (NECB) is an exceptionally rare malignancy, accounting for less than 0. 1% of breast cancers and less than 1% of neuroendocrine tumors Although distant metastases'particularly to the liver'are described, pancreatic involvement remains extraordinarily uncommon…...

12+ hour, 13+ min ago  (286+ words) Cancer Network Background Post-surgical pyoderma gangrenosum (PSPG) is a rare inflammatory dermatosis that can closely mimic infection or flap necrosis after breast surgery Failure to recognize this entity often leads to inappropriate antibiotics and surgical debridement, which worsen disease through…...

16+ hour, 18+ min ago  (99+ words) Cancer Network FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data. According to the press release, Merlin CP-GEP is now the only commercially available melanoma GEP test to…...

17+ hour, 34+ min ago  (220+ words) Full phase 3 MANGROVE trial data will be presented at an upcoming medical meeting, with global regulatory submissions planned for the second half of 2026. The addition of zanubrutinib (Brukinsa) to rituximab (Rituxan) produced superior progression-free survival (PFS) outcomes vs bendamustine (Treanda)…...

17+ hour, 36+ min ago  (165+ words) Cancer Network Updated phase 2a data showed durable survival in a small subset of heavily pretreated patients with advanced pancreatic cancer treated with namodenoson. The open-label phase 2a study enrolled 20 patients with advanced PDAC who had progressed following standard therapies: 14 received namodenoson…...

21+ hour, 46+ min ago  (166+ words) Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission. Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been fundamentally rewritten as a highly manageable chronic condition....

1+ day, 10+ hour ago  (226+ words) Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell'based immunotherapy. All patients (100%) in the experimental arm experienced a neutrophil count of 500/mm3 within 4 weeks of infusion, which included 53 (60. 2%) with neutrophil counts exceeding 500/mm3 for 3 consecutive days. The…...

1+ day, 11+ hour ago  (269+ words) Cancer Network Background American Society of Clinical Oncology (ASCO) guidelines now recommend omission of sentinel lymph node biopsy (SLNB) in specific low-risk patients However, ASCO, SOUND, and INSEMA trials note that nodal status may be needed to guide adjuvant systemic…...

1+ day, 12+ hour ago  (122+ words) In 42 patients with DCIS undergoing breast-conserving surgery, 71. 4% had detectable disseminated cancer cells in bone marrow, with residual-risk DCISion RT score significantly correlated with higher DCC burden compared with low- and elevated-risk groups. Forty-two patients with DCIS underwent BM aspiration and…...